================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------
SCHEDULE TO
AMENDMENT NO. 3
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
EON LABS, INC.
(Name of Subject Company)
NOVARTIS AG
NOVARTIS CORPORATION
ZODNAS ACQUISITION CORP.
(Name of Filing Persons--Offerors)
COMMON STOCK, PAR VALUE $0.01
(Title of Class of Securities)
29412E100
(CUSIP Number of Class of Securities)
George Miller
Head of Legal and General Affairs
Novartis AG
35 Lichtstrasse
CH-4002 Basel, Switzerland
41-61-324-1111
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications on Behalf of Filing Persons)
-Copies to-
Andrew R. Brownstein, Esq.
Trevor S. Norwitz, Esq.
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, NY 10019
(212) 403-1000
-----------
CALCULATION OF FILING FEE
Transaction Valuation Amount of Filing Fee
-------------------------------------------------------
$977,098,158* $115,005*
-------------------------------------------------------
-------------------------------------------------------
* Estimated for purposes of calculating the amount of the filing fee only.
The calculation of the filing fee is described on the cover page to
Amendment No. 1 to the Schedule TO filed on May 27, 2005.
[X] Check the box if any part of the fee is offset as provided by Rule
0-11(a)(2) and identify the filing with which the offsetting fee was
previously paid. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
Amount Previously Paid: $115,005 Filing Party: Novartis Corp.
Form or Registration No.: Schedule TO Date Filed: May 23, 2005
[_] Check the box if the filing relates solely to preliminary communications
made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the
statement relates:
[X] third-party tender offer subject to Rule 14d-1.
[_] issuer tender offer subject to Rule 13e-4.
[_] going-private transaction subject to Rule 13e-3.
[_] amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a final amendment reporting the results
of the tender offer: [_]
================================================================================
This Amendment No. 3 amends and supplements the Tender Offer Statement
on Schedule TO, as amended, (the "SCHEDULE TO"), originally filed with the
Securities and Exchange Commission on May 23, 2005 and as amended and
supplemented by Amendment No. 1 on May 27, 2005 and Amendment No. 2 on June 2,
2005, by Novartis AG, a Swiss Corporation, Novartis Corporation ("NOVARTIS US"),
a New York corporation and an indirect wholly owned subsidiary of Novartis AG,
and Zodnas Acquisition Corp. ("ZODNAS"), a Delaware corporation and an indirect
wholly owned subsidiary of Novartis US. The Schedule TO relates to the offer by
Zodnas to purchase any and all of the outstanding shares of common stock, par
value $0.01 per share (the "SHARES"), of Eon Labs, Inc., a Delaware corporation
("EON"), for $31.00 per Share, net to the seller in cash, upon the terms and
subject to the conditions set forth in the Offer to Purchase, dated May 23, 2005
(the "OFFER TO PURCHASE"), and in the related Letter of Transmittal. Copies of
the Offer to Purchase and the related Letter of Transmittal are filed with the
Schedule TO as exhibits (a)(1)(A) and (a)(1)(B), respectively. Capitalized terms
used and not defined herein shall have the meanings assigned such terms in the
Offer to Purchase and Schedule TO.
ITEMS 1 THROUGH 9 AND 11.
Items 1 through 9 and 11 of the Schedule TO, which incorporate by
reference the information contained in the Offer to Purchase, are hereby amended
and supplemented as follows:
On June 7, 2005, Novartis issued a press release announcing the
completion of its acquisition of Hexal, a copy of which is filed as Exhibit
(a)(5)(D) hereto and is incorporated herein by reference.
ITEM 12. EXHIBITS
Item 12 of the Schedule TO is hereby amended by adding thereto the
following:
(a)(5)(D) Text of Press Release issued by Novartis dated June 7, 2005.
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: June 7, 2005
NOVARTIS AG
By: /s/ George Miller
---------------------------------
Name George Miller
Title: Authorized Signatory
By: /s/ Peter Rupprecht
---------------------------------
Name: Peter Rupprecht
Title: Authorized Signatory
NOVARTIS CORPORATION
By: /s/ Terence A. Barnett
---------------------------------
Name: Terence A. Barnett
Title: President and Chief
Executive Officer
ZODNAS ACQUISITION CORP.
By: /s/ Wayne P. Merkelson
---------------------------------
Name: Wayne P. Merkelson
Title: Vice President
EXHIBIT INDEX
*(a)(1)(A) Offer to Purchase, dated May 23, 2005.
*(a)(1)(B) Form of Letter of Transmittal.
*(a)(1)(C) Form of Notice of Guaranteed Delivery.
*(a)(1)(D) Form of Letter to Brokers, Dealers, Commercial Banks, Trust
Companies and Other Nominees.
*(a)(1)(E) Form of Letter to Clients for use by Brokers, Dealers, Commercial
Banks, Trust Companies and Other Nominees.
*(a)(1)(F) Guidelines for Certification of Taxpayer Identification Number
(TIN) on Substitute Form W-9.
(a)(2) Not applicable.
(a)(3) Not applicable.
(a)(4) Not applicable.
*(a)(5)(A) Text of Press Release issued by Novartis dated February 21, 2005,
incorporated in this Schedule TO by reference to the Schedule TO
filed by Novartis AG, Novartis US and Zodnas on February 22, 2005.
*(a)(5)(B) Form of Summary Advertisement published in The Wall Street Journal
on May 23, 2005.
*(a)(5)(C) Text of Press Release issued by Novartis dated May 27, 2005.
(a)(5)(D) Text of Press Release issued by Novartis dated June 7, 2005.
*(a)(6)(A) Complaint titled Ellen Wiehl v. Eon Labs, Inc. et al., filed on
February 22, 2005, in the Chancery Court of the State of Delaware,
County of New Castle.
*(a)(6)(B) Complaint titled Paulena Partners LLC v. Eon Labs, Inc. et al.,
filed on February 22, 2005, in the Chancery Court of the State of
Delaware, County of New Castle.
*(a)(6)(C) Complaint titled Robert Kemp, IRRA v. Eon Labs, Inc. et al., filed
on February 22, 2005, in the Chancery Court of the State of
Delaware, County of New Castle.
*(a)(6)(D) Complaint titled Peter J. Calcagno v. Eon Labs, Inc. et al., filed
on February 23, 2005, in the Chancery Court of the State of
Delaware, County of New Castle.
*(a)(6)(E) Complaint titled Christopher Pizzo v. Novartis AG et al., filed on
February 23, 2005, in the Supreme Court of the State of New York,
County of New York.
*(a)(6)(F) Complaint titled Erste Sparinvest Kapitalanlagegesellschaft MBH v.
Eon Labs, Inc. et al., filed on March 1, 2005, in the Chancery
Court of the State of Delaware, County of New Castle.
*(a)(6)(G) Complaint titled Merl Huntsinger v. Eon Labs, Inc. et al., filed on
March 1, 2005, in the Chancery Court of the State of Delaware,
County of New Castle.
*(a)(6)(H) Complaint titled Jason Hung v. Eon Labs, Inc. et al., filed on
March 3, 2005, in the Chancery Court of the State of Delaware,
County of New Castle.
*(a)(6)(I) Consolidated Amended Complaint titled In re Eon Labs, Inc.
Shareholders Litigation, filed on May 27, 2005, in the Chancery
Court of the State of Delaware, County of New Castle.
(b) None.
*(d)(1) Agreement and Plan of Merger, dated as of February 20, 2005, by and
among Novartis US, Zodnas, Eon and, for purposes of Section 12
thereof only, Novartis AG, incorporated in this Schedule TO by
reference to Exhibit 2.2 to the Schedule 13D filed by Novartis US,
Novartis AG and Zodnas on March 2, 2005.
*(d)(2) Agreement for Purchase and Sale of Stock, dated as of February 20,
2005, by and between Novartis US, Santo and, for purposes of
Section 10.12 thereof only, Novartis AG, incorporated in this
Schedule TO by reference to Exhibit 2.1 to the Schedule 13D filed
by Novartis US, Novartis AG and Zodnas on March 2, 2005.
*(d)(3) Confidentiality Agreement, by and between Novartis US and Eon,
dated as of February 11, 2005, incorporated in this Schedule TO by
reference to Exhibit 2.3 to the Schedule 13D filed by Novartis US,
Novartis AG and Zodnas on March 2, 2005.
(g) None.
(h) Not applicable.
------------------------
* Previously filed.